Working with Cytel, Merck Gains Validated, Early Stage Adaptive Trial Decision-making and Design Tools
Merck Research Labs biostatisticians pioneer new methods for conducting dose-finding trials that flexibly adapt allocation rules to focus on doses eliciting desirable responses. But deployment is delayed when they cannot find commercial software to test and validate their models.
Response – Cytel biostatisticians and software developers collaborate with Merck counterparts
Cytel builds an intuitive Multiple Document Interface enables concurrent simulations of several trial designs and easy comparison of differing dose levels and response variances.
With its own trial simulation tool, Merck better assesses the trade-offs between different frequentist and Bayesian adaptive trial approaches including predictions of recruitment patterns and drug supply dynamics.